Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site

To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Veterinary anaesthesia and analgesia 2011-07, Vol.38 (4), p.374-384
Hauptverfasser: Messenger, Kristen M, Davis, Jennifer L, LaFevers, Douglas H, Barlow, Beth M, Posner, Lysa P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 384
container_issue 4
container_start_page 374
container_title Veterinary anaesthesia and analgesia
container_volume 38
creator Messenger, Kristen M
Davis, Jennifer L
LaFevers, Douglas H
Barlow, Beth M
Posner, Lysa P
description To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg. In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility. Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported. Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.
doi_str_mv 10.1111/j.1467-2995.2011.00613.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_872132708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1467298716306729</els_id><sourcerecordid>872132708</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</originalsourceid><addsrcrecordid>eNqNkUtv1TAQhS0EoqXwF5B3rBL8SpwgNpdCH1IFAhXKbuQ4E65v88JOyu2_xyHlbsEbjzznnNF8JoRylvJ4Xu9SrnKdiLLMUsE4TxnLuUz3j8jxofH4UBf6iDwLYccY12XGnpIjwTPGpebHxF72kzd32A9zoKavaZir1vU_ZtPSah59bPhx63qkrqfbwQcMb-i4Nb4zdriN75Ozq9H1TTtjb5EODQ2mG5cYGtyEz8mTxrQBXzzcJ-Tr2Yfr04vk6tP55enmKrEqVzJRBispjBZc5JWWhRWVqHiZYWOVzsqGNUqpUhqpLKttroqC2bpWuhSS2Tzuf0JerbmjH37OGCboXLDYtqbHuB4UMVoKzYqoLFal9UMIHhsYveuMvwfOYCEMO1jgwQISFsLwhzDso_Xlw5C56rA-GP8ijYK3q-CXa_H-v4Ph22YTi2hPVrsLE-4PduNvIddSZ3Dz8Rwubt5__3L2-RpY1L9b9RjJ3jn0EKxbvqF2Hu0E9eD-vdRva9KvKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872132708</pqid></control><display><type>article</type><title>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Messenger, Kristen M ; Davis, Jennifer L ; LaFevers, Douglas H ; Barlow, Beth M ; Posner, Lysa P</creator><creatorcontrib>Messenger, Kristen M ; Davis, Jennifer L ; LaFevers, Douglas H ; Barlow, Beth M ; Posner, Lysa P</creatorcontrib><description>To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg. In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility. Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported. Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.</description><identifier>ISSN: 1467-2987</identifier><identifier>EISSN: 1467-2995</identifier><identifier>DOI: 10.1111/j.1467-2995.2011.00613.x</identifier><identifier>PMID: 21501371</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Administration, Sublingual ; analgesia ; Analgesics, Opioid - administration &amp; dosage ; Analgesics, Opioid - blood ; Analgesics, Opioid - pharmacokinetics ; Animals ; Biological Availability ; Blood Chemical Analysis - methods ; Blood Chemical Analysis - veterinary ; buprenorphine ; Buprenorphine - administration &amp; dosage ; Buprenorphine - analogs &amp; derivatives ; Buprenorphine - blood ; Buprenorphine - pharmacokinetics ; Cross-Over Studies ; equine ; Horses - metabolism ; Injections, Intravenous - veterinary ; Jugular Veins ; Male ; opioids ; pharmacokinetics ; Prospective Studies ; sampling site</subject><ispartof>Veterinary anaesthesia and analgesia, 2011-07, Vol.38 (4), p.374-384</ispartof><rights>2011 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia.</rights><rights>2011 The Authors. Veterinary Anaesthesia and Analgesia. © 2011 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists</rights><rights>2011 The Authors. Veterinary Anaesthesia and Analgesia. © 2011 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesiologists.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</citedby><cites>FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1467-2995.2011.00613.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1467-2995.2011.00613.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21501371$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Messenger, Kristen M</creatorcontrib><creatorcontrib>Davis, Jennifer L</creatorcontrib><creatorcontrib>LaFevers, Douglas H</creatorcontrib><creatorcontrib>Barlow, Beth M</creatorcontrib><creatorcontrib>Posner, Lysa P</creatorcontrib><title>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</title><title>Veterinary anaesthesia and analgesia</title><addtitle>Vet Anaesth Analg</addtitle><description>To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg. In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility. Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported. Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.</description><subject>Administration, Sublingual</subject><subject>analgesia</subject><subject>Analgesics, Opioid - administration &amp; dosage</subject><subject>Analgesics, Opioid - blood</subject><subject>Analgesics, Opioid - pharmacokinetics</subject><subject>Animals</subject><subject>Biological Availability</subject><subject>Blood Chemical Analysis - methods</subject><subject>Blood Chemical Analysis - veterinary</subject><subject>buprenorphine</subject><subject>Buprenorphine - administration &amp; dosage</subject><subject>Buprenorphine - analogs &amp; derivatives</subject><subject>Buprenorphine - blood</subject><subject>Buprenorphine - pharmacokinetics</subject><subject>Cross-Over Studies</subject><subject>equine</subject><subject>Horses - metabolism</subject><subject>Injections, Intravenous - veterinary</subject><subject>Jugular Veins</subject><subject>Male</subject><subject>opioids</subject><subject>pharmacokinetics</subject><subject>Prospective Studies</subject><subject>sampling site</subject><issn>1467-2987</issn><issn>1467-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1TAQhS0EoqXwF5B3rBL8SpwgNpdCH1IFAhXKbuQ4E65v88JOyu2_xyHlbsEbjzznnNF8JoRylvJ4Xu9SrnKdiLLMUsE4TxnLuUz3j8jxofH4UBf6iDwLYccY12XGnpIjwTPGpebHxF72kzd32A9zoKavaZir1vU_ZtPSah59bPhx63qkrqfbwQcMb-i4Nb4zdriN75Ozq9H1TTtjb5EODQ2mG5cYGtyEz8mTxrQBXzzcJ-Tr2Yfr04vk6tP55enmKrEqVzJRBispjBZc5JWWhRWVqHiZYWOVzsqGNUqpUhqpLKttroqC2bpWuhSS2Tzuf0JerbmjH37OGCboXLDYtqbHuB4UMVoKzYqoLFal9UMIHhsYveuMvwfOYCEMO1jgwQISFsLwhzDso_Xlw5C56rA-GP8ijYK3q-CXa_H-v4Ph22YTi2hPVrsLE-4PduNvIddSZ3Dz8Rwubt5__3L2-RpY1L9b9RjJ3jn0EKxbvqF2Hu0E9eD-vdRva9KvKg</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Messenger, Kristen M</creator><creator>Davis, Jennifer L</creator><creator>LaFevers, Douglas H</creator><creator>Barlow, Beth M</creator><creator>Posner, Lysa P</creator><general>Elsevier Ltd</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201107</creationdate><title>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</title><author>Messenger, Kristen M ; Davis, Jennifer L ; LaFevers, Douglas H ; Barlow, Beth M ; Posner, Lysa P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4643-4aeb32a72126b738c2b2b195efc4759f0f44493a34c0dc64880cdd479230c6613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Administration, Sublingual</topic><topic>analgesia</topic><topic>Analgesics, Opioid - administration &amp; dosage</topic><topic>Analgesics, Opioid - blood</topic><topic>Analgesics, Opioid - pharmacokinetics</topic><topic>Animals</topic><topic>Biological Availability</topic><topic>Blood Chemical Analysis - methods</topic><topic>Blood Chemical Analysis - veterinary</topic><topic>buprenorphine</topic><topic>Buprenorphine - administration &amp; dosage</topic><topic>Buprenorphine - analogs &amp; derivatives</topic><topic>Buprenorphine - blood</topic><topic>Buprenorphine - pharmacokinetics</topic><topic>Cross-Over Studies</topic><topic>equine</topic><topic>Horses - metabolism</topic><topic>Injections, Intravenous - veterinary</topic><topic>Jugular Veins</topic><topic>Male</topic><topic>opioids</topic><topic>pharmacokinetics</topic><topic>Prospective Studies</topic><topic>sampling site</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Messenger, Kristen M</creatorcontrib><creatorcontrib>Davis, Jennifer L</creatorcontrib><creatorcontrib>LaFevers, Douglas H</creatorcontrib><creatorcontrib>Barlow, Beth M</creatorcontrib><creatorcontrib>Posner, Lysa P</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Veterinary anaesthesia and analgesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Messenger, Kristen M</au><au>Davis, Jennifer L</au><au>LaFevers, Douglas H</au><au>Barlow, Beth M</au><au>Posner, Lysa P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site</atitle><jtitle>Veterinary anaesthesia and analgesia</jtitle><addtitle>Vet Anaesth Analg</addtitle><date>2011-07</date><risdate>2011</risdate><volume>38</volume><issue>4</issue><spage>374</spage><epage>384</epage><pages>374-384</pages><issn>1467-2987</issn><eissn>1467-2995</eissn><abstract>To describe the pharmacokinetics and adverse effects of intravenous (IV) and sublingual (SL) buprenorphine in horses, and to determine the effect of sampling site on plasma concentrations after SL administration. Randomized crossover experiment; prospective study. Eleven healthy adult horses between 6 and 20 years of age and weighing 487–592 kg. In the first phase; buprenorphine was administered as a single IV or SL dose (0.006 mg kg−1) and pharmacokinetic parameters were determined for each route of administration using a noncompartmental model. In the second phase; the jugular and lateral thoracic veins were catheterized for simultaneous venous blood sampling, following a dose of 0.006 mg kg−1 SL buprenorphine. For both phases, plasma buprenorphine concentrations were measured using ultra-performance liquid chromatography with mass spectrometry. At each sampling period, horses were assessed for behavioral excitement and gastrointestinal motility. Following IV administration, buprenorphine mean ± SD half-life was 5.79 ± 1.09 hours. Systemic clearance (Cl) following IV administration was 6.13 ± 0.86 mL kg−1 minute−1 and volume of distribution at steady-state was 3.16 ± 0.65 L kg−1. Following IV administration, horses showed signs of excitement. Gastrointestinal sounds were decreased following both routes of administration; however, none of the horses exhibited signs of colic. There was a significant discrepancy between plasma buprenorphine concentrations measured in the jugular vein versus the lateral thoracic vein following phase 2, thus pharmacokinetic parameters following SL buprenorphine are not reported. Buprenorphine has a long plasma half-life and results in plasma concentrations that are consistent with analgesia in other species for up to 4 hours following IV administration of this dose in horses. While buprenorphine is absorbed into the circulation following SL administration, jugular venous sampling gave a false measurement of the quantity absorbed and should not be used to study the uptake from SL administration.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>21501371</pmid><doi>10.1111/j.1467-2995.2011.00613.x</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1467-2987
ispartof Veterinary anaesthesia and analgesia, 2011-07, Vol.38 (4), p.374-384
issn 1467-2987
1467-2995
language eng
recordid cdi_proquest_miscellaneous_872132708
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection
subjects Administration, Sublingual
analgesia
Analgesics, Opioid - administration & dosage
Analgesics, Opioid - blood
Analgesics, Opioid - pharmacokinetics
Animals
Biological Availability
Blood Chemical Analysis - methods
Blood Chemical Analysis - veterinary
buprenorphine
Buprenorphine - administration & dosage
Buprenorphine - analogs & derivatives
Buprenorphine - blood
Buprenorphine - pharmacokinetics
Cross-Over Studies
equine
Horses - metabolism
Injections, Intravenous - veterinary
Jugular Veins
Male
opioids
pharmacokinetics
Prospective Studies
sampling site
title Intravenous and sublingual buprenorphine in horses: pharmacokinetics and influence of sampling site
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T00%3A39%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20and%20sublingual%20buprenorphine%20in%20horses:%20pharmacokinetics%20and%20influence%20of%20sampling%20site&rft.jtitle=Veterinary%20anaesthesia%20and%20analgesia&rft.au=Messenger,%20Kristen%20M&rft.date=2011-07&rft.volume=38&rft.issue=4&rft.spage=374&rft.epage=384&rft.pages=374-384&rft.issn=1467-2987&rft.eissn=1467-2995&rft_id=info:doi/10.1111/j.1467-2995.2011.00613.x&rft_dat=%3Cproquest_cross%3E872132708%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=872132708&rft_id=info:pmid/21501371&rft_els_id=S1467298716306729&rfr_iscdi=true